Injective and Litecoin Price Forecast — KangaMoon Surges

• Injective (INJ) price has fallen below $40 and may struggle despite recent network developments.
• Litecoin (LTC) could break above $100 and see further upside amid ETF speculation.
• Elsewhere, investors are aggressively buying KangaMoon (KANG).

Litecoin (LTC) is seeing renewed activity amid rising news coverage while Injective (INJ) sits at a critical support level. Both cryptocurrencies are on investors’ radar as bullish Bitcoin sentiment casts a favorable light over top altcoins.

Below are price outlooks for Litecoin and Injective and an explanation of why interest in the new crypto project KangaMoon (KANG) is surging.

Litecoin price outlook amid LTC news

Litecoin was once among the stronger altcoins before fading during the last bear market. Now, with Bitcoin grabbing headlines after a fresh all-time high, Litecoin is gradually returning to focus. Renewed attention could revive sentiment for the asset.

Last week, Coinbase Derivatives signaled plans to list Litecoin futures, and that product is scheduled to launch on April 1. Meanwhile, the CFTC has identified LTC and ETH in filings related to the lawsuit against the KuCoin exchange.

There is also speculation that institutions could consider an LTC spot exchange-traded fund (ETF). Litecoin’s similarities to Bitcoin make it more likely—relative to Ethereum—to be seen favorably by regulators, which fuels ETF rumors.

While ETF speculation remains uncertain, a bullish breakout above $100 would support a stronger Litecoin outlook. LTC jumped more than 10% late Tuesday to reach highs near $98.90. If price clears the immediate resistance, Litecoin could retest the $130 area. Momentum at those levels might push LTC/USD toward a multiyear high above $200.

Injective (INJ) has been volatile since falling from its all-time high of $52.60 on March 14. Currently trading around $38.35, INJ is down more than 5% over the past 24 hours.

The price of INJ is hovering near a key support line that has offered buyers a reload opportunity several times this year. Recent weakness comes as investors assess the market impact of charges against KuCoin and two of its founders.

The U.S. Department of Justice has accused two KuCoin executives of criminal wrongdoing, and KCS price reacted with declines. Injective’s fundamentals, however, show notable network growth. Its Ionic upgrade promises increased interoperability with Ethereum, Solana and other chains—an improvement that could drive bullish sentiment.

If bulls reclaim momentum, Injective could target a move above $50 and potentially a new all-time high. If buyers fail to take control, a pullback to the $40–$35 range is possible. The next upside level sits near $45, while bears may aim to test the $30 support level.

KangaMoon (KANG) is a new crypto token currently in presale. Although it has not yet launched on exchanges, it is drawing significant attention for both its project design and the potential of its native token.

KangaMoon’s tokenomics incentivize presale participants to earn KANG through challenges and competitions. The project blends meme-token dynamics with SocialFi and play-to-earn mechanics, creating engagement through tasks and rewards.

There is potential for KangaMoon to become a notable play-to-earn title, especially given its rare NFTs and battle arena feature, which add excitement and community utility.

To date, the project has raised over $2.8 million from early backers. Phase 4 of the presale is nearly 40% sold, with the current price offered at a discounted $0.014—up from $0.005 in phase 1. When tokens hit exchanges after the presale, KangaMoon could be among the projects that see rapid appreciation.

Presale participants can currently receive a 10% bonus on purchases. Accepted payment options include USDC, USDT, SOL, BNB, ETH and BTC.

For more information, visit the KangaMoon site: KangaMoon